A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

Exclusion Criteria

• •Histology other than adenocarcinoma (neuroendocrine or acinar cell)
• •Suspected, known, or central nervous system (CNS) metastases (Imaging required only if participants are symptomatic)
• •Active, known or suspected autoimmune disease
• •Condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administration
• •Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity
• •Prior treatment with cysteine-cysteine chemokine receptor 2 (CCR2) and/or cysteine-cysteine chemokine receptor 5 (CCR5) inhibitors, programmed death-1 receptor (PD-1), programmed death-ligand 1 \[PD(L)-1\] or cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibodies
• •History of allergy to study treatments or any of its components of the study arm that participant is enrolling